AlloEx
Phase 1Cell therapy
AlloEx is one of 55 biologic programs targeting Mesenchymal Stem Cell. It is currently in Phase 1.
4
Indications
5
Total Trials
4
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
150 competitors in Stroke
#DrugCompanyPhaseTrials
1Zometa
PfizerPreclinical
Savella
AbbViePreclinical
Proamatine
TakedaPreclinical
Repatha
AmgenPreclinical
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Zantac 150
CChattem
Preclinical
Alka-Seltzer
AAbbott
Preclinical
Haldol
DDePuy Orthopaedics
Preclinical
AlloEx
TThe Foundation for Orthopaedics and Regenerative Medicine
Phase 1
Inderal
Mylan Pharmaceuticals IncPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Stroke1 trial
Mesenchymal Stem Cell1 trial
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Exosomes for Parkinson's Disease
Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05152394·20 enrolled
Congenital Myasthenic Syndrome1 trial
Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution
Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT07226726·20 enrolled
Motor Disorders1 trial
Patients With ALS and Other Motor Disorders Will be Treated With Mesenchymal Cell Exosome Solution
Completed·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT07105371·18 enrolled
Trigeminal Neuralgia1 trial
Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells Exosomes for Trigeminal Neuralgia
Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05152368·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AlloEx. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details